Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
Ortho Tri-Cyclen is an oral contraceptive tablet containing a norgestimate/ethinyl estradiol combination in a triphasic formulation. It prevents pregnancy through hormonal suppression of ovulation and cervical mucus thickening. The product is indicated for contraception in women of reproductive age.
LOE-approaching lifecycle signals team focus on retention and generic defense strategies; commercial headcount likely stable or transitioning to support extension products.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects
To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)
Ortho Tri-Cyclen roles focus on brand defense, generic mitigation, and patient retention in a mature market. Career growth opportunities are limited; positions emphasize execution and loyalty over innovation.
Worked on ORTHO TRI-CYCLEN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.